Natus predicts 20% revenue soar in 2013

Devicemaker Natus Medical ($BABY) pulled in a record $90.5 million in revenue last quarter, and the company is projecting another boom in 2013, figuring sales will grow up to 20%.

In addition to its core business of pediatric devices, Natus is building up its heft in the neurodiagnostics world through M&A. Last year, the company bought Nicolet, CareFusion's ($CFN) neurodiagnostics arm, for $58 million, and Natus scooped up Astra-Med's ($ALOT) similar Grass Technologies unit in January for $18.6 million.

Those deals, coupled with Natus' growing share of the monitoring market, will push 2013 revenues up to about $367 million, the company figures, a huge boost over 2012's $291.7 million.

"We successfully integrated the Nicolet sales organization into Natus during the fourth quarter, creating what we believe to be the largest sales and service organization in the world selling into the neurodiagnostic market," CEO Jim Hawkins said in a statement. "After first entering this market only 7 years ago, we have now become the worldwide market leader. We are very proud of this accomplishment."

Between Nicolet and Grass Technologies, Natus has expanded its international presence, boosted its disposable offerings and doubled down on its neurodiagnostic R&D capabilities, Hawkins said, and now the company is poised for more record revenue.

- read Natus' full results

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.